Each week we scan PubMed and Europe PMC for new studies on GLP-1 medications and muscle, lean mass, protein, and training, then summarize the relevant ones with a link to every source. Neutral summaries, not medical advice.
Week of October 6-12, 2026
This review, published in a physiology journal, focuses specifically on the effects of GLP-1 receptor agonists on lean tissue—skeletal muscle and bone—beyond their well-known impac
Read the roundup →Week of September 29 - October 5, 2026
This scientific statement from the Polish Society of Dietetics summarises nutritional challenges during incretin-based therapy, including reduced energy intake, gastrointestinal si
Read the roundup →Week of September 22-28, 2026
This hypothesis paper (not a clinical trial) proposes that the rapid weight loss, reduced energy and protein intake, decreased mechanical loading, and potentially lower physical ac
Read the roundup →Week of September 15-21, 2026
This prespecified secondary analysis of the phase 3b STEP UP trial used MRI to assess body composition in 55 participants (49 on semaglutide, 6 on placebo) over 72 weeks. Semagluti
Read the roundup →Week of September 8-14, 2026
This systematic review and meta-analysis of 60 studies (46 RCTs, 13 real-world studies, over 1.25 million individuals) found that GLP-1 receptor agonists—including semaglutide, lir
Read the roundup →Week of September 1-7, 2026
This narrative review proposes that a meaningful portion of the lean mass reduction observed during GLP-1 receptor agonist therapy may represent a physiological adaptation to reduc
Read the roundup →Week of August 25-31, 2026
This expert position statement from the Spanish Menopause Society synthesizes evidence on incretin-based therapies (including semaglutide and tirzepatide) in peri- and postmenopaus
Read the roundup →Week of August 18-24, 2026
This review examines the risk that appetite suppression from GLP-1 and GIP/GLP-1 receptor agonists may reduce absolute protein intake, potentially compromising muscle health in old
Read the roundup →Week of August 11-17, 2026
The European Federation of Internal Medicine (EFIM) adapted existing sarcopenia clinical practice guidelines specifically for adults with multiple chronic conditions (multimorbidit
Read the roundup →Week of August 4-10, 2026
This perspective piece in Trends in Endocrinology and Metabolism argues that the expanding use of GLP-1 receptor agonists in older adults raises underappreciated concerns about mus
Read the roundup →Week of July 29 - August 4, 2026
This perspective piece (not an original trial) argues that GLP-1 therapy during adolescence—a period of rapid muscle and bone accrual—may attenuate peak musculoskeletal development
Read the roundup →Week of July 21-27, 2026
This preprint used primary human myotubes isolated from older adults with obesity to test whether semaglutide or GIP directly causes muscle atrophy or impairs myogenesis. Neither t
Read the roundup →Week of July 14-20, 2026
In a 14-week mouse study using a diet-induced obesity model, semaglutide alone reduced fat mass by 31% but also reduced lean mass by 11%. Combining semaglutide with exercise furthe
Read the roundup →Week of July 7-13, 2026
This narrative review examines how incretin mimetics affect skeletal muscle mass, bone mineral density, and physical function in older adults. The authors identified six weight-red
Read the roundup →Week of July 5-11, 2026
This large systematic review and network meta-analysis in the BMJ analyzed 262 randomized controlled trials (99,791 participants) comparing 19 weight-loss drugs. At one year, tirze
Read the roundup →
MuscleOnGLP